{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:22:20Z","timestamp":1788355340901,"version":"build-2803163510"},"reference-count":11,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.transproceed.2020.08.025","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T17:42:39Z","timestamp":1599759759000},"page":"1058-1063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Opportunistic Infections After Induction With Alemtuzumab or Basiliximab: A 3-Year Kidney Transplantation Experience"],"prefix":"10.1016","volume":"53","author":[{"given":"Diana F.","family":"Florescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre C.","family":"Kalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Bremers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott G.","family":"Westphal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2020.08.025_bib1","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation","volume":"355","author":"Brennan","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2020.08.025_bib2","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1009546","article-title":"Alemtuzumab induction in renal transplantation","volume":"364","author":"Hanaway","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2020.08.025_bib3","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1432-2277.2012.01448.x","article-title":"Alemtuzumab as compared to alternative contemporary induction regimens","volume":"25","author":"LaMattina","year":"2012","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2020.08.025_bib5","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/TP.0b013e318257ad41","article-title":"Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis","volume":"93","author":"Morgan","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2020.08.025_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1399-3062.2011.00706.x","article-title":"A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group","volume":"14","author":"George","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.transproceed.2020.08.025_bib7","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(14)61095-3","article-title":"Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C study): a randomised trial","volume":"384","author":"Haynes","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.transproceed.2020.08.025_bib8","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/TP.0b013e3182a64db9","article-title":"Alemtuzumab induction in renal transplantation permits safe steroid avoidance with tacrolimus monotherapy: a randomized controlled trial","volume":"96","author":"Welberry Smith","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2020.08.025_bib9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/ajh.20780","article-title":"Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab","volume":"82","author":"Cheung","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.transproceed.2020.08.025_bib10","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1086\/510388","article-title":"Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody","volume":"44","author":"Peleg","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2020.08.025_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5414\/CN109934","article-title":"Alemtuzumab induction for retransplantation after primary transplant with alemtuzumab induction","volume":"93","author":"Descourouez","year":"2020","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.transproceed.2020.08.025_bib12","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1097\/TP.0b013e31822ca7ca","article-title":"Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy---an open label, randomized trial","volume":"92","author":"Chan","year":"2011","journal-title":"Transplantation"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134520305546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134520305546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:38:54Z","timestamp":1758577134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134520305546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0041134520305546"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2020.08.025","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opportunistic Infections After Induction With Alemtuzumab or Basiliximab: A 3-Year Kidney Transplantation Experience","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2020.08.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}